alanine and phenylpyruvate (Jervis & Drejza, 1966) . Various estimates are available of the plasma concentration to which phenylpyruvate may rise in phenylketonuria (Harris, 1959; Jervis & Drejza, 1966; Small et al., 1970; Patel, 1972) , the highest of these being in the region of 0.5mM (Patel, 1972) . Phenylketonuria may give rise to severe brain malfunction and is particularly characterized by a deficiency in myelin deposition in the nervous tissue. Weber etal. (1970) have shown effects of phenylpyruvate on both brain hexokinase and 6-phosphogluconate dehydrogenase, establishing an apparent K1 of phenylpyruvate in the range 3-6mM. They have also demonstrated that phenylalanine inhibits pyruvate kinase with an apparent Kg of 9mM. Bowden & McArthur (1972) have shown that phenylpyruvate inhibits pyruvate decarboxylation in rat brain homogenates with an apparent K, of 6mM. They have suggested that the inhibition of the pyruvate dehydrogenase complex may be a primary enzymic defect characteristic of phenylketonuria.
We have sought to test this hypothesis more rigorously by using a more purified enzyme source (rat brain mitochondrial extract) and an assay system distinct from the decarboxylation assay of Bowden & McArthur (1972) . In this assay method the pyruvate dehydrogenase-complex activity is monitored by using a coupling enzyme, the pigeon liver arylamine acetyltransferase (EC 2.3.1.5 (Land & Clark, 1972 Ochoa (1955) and the purity was assayed by titration of free thiol groups with 2,2'-bipyridyl disulphide. All other compounds were of the highest quality available commercially and reagents were made up in doubleglass-distilled water.
Animals
Male albino rats of the Wistar strain (155-175 g body wt.) were used for all experiments and were fed ad lib. on laboratory diet no. 1 (Spratts, Reading, Berks., U.K.). Mitochondria were prepared from rat brain cortex by the method ofClark & Nicklas (1970) . Pyruvate dehydrogenase activity was measured in mitochondrial preparations that had been frozen and thawed three times. Preliminary experiments showed that this assay followed linear kinetics up to 3mg of mitochondrial protein (approx. 1 mg was used as a routine) and for at least 30min (the time used as a routine).
By coupling with pigeon liver arylamine acetyltransferase. This assay couples the acetyl group of acetyl-CoA formed by pyruvate dehydrogenase to an azo dye and the formation of the acetyl-p-(p-aminophenylazo)benzenesulphonic acid is monitored by the decrease in E460. The acetyl transfer is catalysed by pigeon liver arylamine acetyltransferase, which was prepared from pigeon liver acetone-dried powder as described by Tabor et al. (1953) , except that 20mM-potassium phosphate buffer, pH7.8, was required to elute the enzyme from the alumina gel (mainly in the third and fourth washings; each wash was lOml of eluent, and enzyme concentration was approx. 2.5mg of protein/ml) and was assayed by the method of Jacobson (1961) .
The reaction mixture was essentially as described by Coore et al. (1971) . In a final volume of 2ml the following were present (final concentrations): lOOmdm- (Gornall et al., 1949) .
Evaluation ofresults
In all cases where appropriate, the best lines through a series of points have been calculated by linear regression methods with the aid of a computer program.
Results
Effect ofphenylpyruvate on brain pyruvate dehydrogenase-complex activity as measured by decarboxylation of [1-14C] pyruvate
The results of the experiments are presented in Table 1 , which shows that no significant inhibition of pyruvate decarboxylation by phenylpyruvate occurs up to concentrations of 2mM-phenylpyruvate. At higher concentrations some inhibition is apparent, more than 40% inhibition occurring at 10mM-phenylpyruvate at saturating pyruvate concentrations. It is unlikely therefore that in phenylketonuria phenylpyruvate has any direct effect on pyruvate decarboxylation, since the highest recorded tissue phenylpyruvate concentrations are an order of magnitude below this (Patel, 1972 (1972) may be due to an increased acetyl-CoA/CoA or NADH/NAD+ ratio, since in the method of assay (Bowden et al., 1971) used by them no exogenous CoA nor any NADH-reoxidizing system is present. It is well established in other tissues that increases in either of these ratios inhibit pyruvate dehydrogenase activity (Hansen & Henning, 1966) .
Effect ofphenylpyruvate on pyruvate dehydrogenasecomplex activity as measured by the coupling enzyme arylamine acetyltransferase Fig. 1 shows a classical reciprocal plot of rat brain pyruvate dehydrogenase-complex activity at various pyruvate concentrations as assayed by the coupled assay of Coore et al. (1971) , 1971) . There is, however, some discrepancy between the Vmax. value reported here and the much higher oxygen uptakes for rat brain mitochondria oxidizing pyruvate reported recently by Cremer et al. (1972) .
If pyruvate dehydrogenase-complex activity is measured in the presence of phenylpyruvate no inhibition of the pyruvate dehydrogenase complex per se is observed, provided that the coupling enzyme is maintained in excess (see Fig. 2 ). To obtain this it is necessary to add additional amounts of coupling enzyme; for example, in the presence of 3 mM-phenylpyruvate a total of 1.5mg ofcoupling-enzyme protein (600,1) has to be present for full expression of pyruvate dehydrogenase-complex activity, as opposed to only 0.5mg of coupling-enzyme protein (200,u1) required in the absence of any inhibitor. Fig. 2(a) shows the decrease in the rate of acetyl-CoA transfer in the coupled assay in the presence of increasing concentrations of phenylpyruvate, with the restoration of the original activity on the addition of further coupling enzyme (Fig. 2b) . These results suggest that phenylpyruvate is acting as an inhibitor of the coupling enzyme.
Effect of phenylpyruvate on pigeon liver arylamine acetyltransferase
The hypothesis that phenylpyruvate was inhibiting the acetyltransferase was further supported by studies with the acetyltransferase alone. The activity of this enzyme was measured in the presence of various concentrations of phenylpyruvate at three different acetyl-CoA concentrations. The results are plotted in Fig. 3 and show a classical competitive inhibition with an apparent K, of 100PM for phenylpyruvate.
Studies with other acetyl donors, e.g. p-nitroacetanilide, also show inhibition by phenylpyruvate.
Discussion
The results reported here do not lend support to the hypothesis that the inhibition of pyruvate dehydrogenase by phenylpyruvate is a primary enzymic defect in phenylketonuria (Bowden & McArthur, 1973 / \cH2-c-co2H iI ( (Patel, 1972) .
However, the observations reported here on the effects of phenylpyruvate on acetyl-group transfer by the pigeon liver arylamine acetyltransferase may have important metabolic implications for phenylketonuria as well as being of interest in themselves. Evidence for this is presented in the accompanying paper (Land & Clark, 1973) .
The nature of the competition between phenylpyruvate and the acetyl group must lie in common structure and functional features. Phenylpyruvate may theoretically exist in a number of different forms, shown in Scheme 1. The titration of phenylpyruvate reveals two apparent pK values, one at pH 6.5 and the other at pH 12.1. The former probably represents a conglomerate of dissociation and equilibrium constants associated with the formation of the carboxyl anion and the keto/enol equilibrium. However, the pKat 12.1 is associated with the appearance of a large absorption maximum at 320nm and probably represents the formation of the enolate anion (III) (Errara & Greenstein, 1947 ; J. M. Land & J. B. Clark, un- Vol. 134 published work). Spectral studies on phenylpyruvate at pH9and 12.75 suggestthatthe form (IIC) ofphenylpyruvate does not exist to any appreciable extent and that the keto form of the anion (IIA), is the predominant species present at pH9. As the enol form (IIB) contributes to the absorption at 320nm but the keto form (IIA) does not (Errara & Greenstein, 1947) it is possible to calculate that the keto form (IIA) of the phenylpyruvate anion predominates (96%) at the pH at which the assays were run. Two possibilities therefore exist: (a) that the inhibition is a property of the predominant species present, the keto form (IIA) of phenylpyruvate, or (b) that a very effective inhibition is occurring by means of the small concentration of the enol form (IIB) present (i.e. the inhibition constant of the enol form must be almost two orders of magnitude smaller than the keto form). As phenylpyruvate inhibits the acetyltransferase with similar inhibition constants when both acetyl CoA and pnitroacetanilide are used as acetyl donors, it is possible that the competition is occurring with respect to the acetyl group of acetyl-CoA. Both the keto form of phenylpyruvate (IIA) and the two acetyl donors (acetyl-CoA and p-nitroacetanilide) have in common the X-CH2-CO-Y spatial grouping. Further preliminary studies with phenylacetaldehyde, which also contains this grouping, show that this compound is also an effective inhibitor of acetyl transfer, thus lending support to the hypothesis that it is the keto form of phenylpyruvate (IIA) that is the inhibitory species.
